Topics

Adverum Biotechnologies to Present 30-month Preclinical Safety and Expression Data for ADVM-022 ...

01:00 EDT 2 May 2019 | BioMedReports - Blog

- Oral Presentation Today at 10:45 am ET at the ASGCT 22nd Annual Meeting -

- ADVM-022 Was Demonstrated to be Safe and Well Tolerated, Provided Long-term, Sustained Aflibercept Expression out to 30 Months Following a Single Intravitreal Injection -

- Long-term Aflibercept Expression and VEGF Suppression Did Not Affect Retina Structure or Function -

MENLO PARK, Calif., May 02, 2019 (GLOBE NEWSWIRE)

Read more...

Original Article: Adverum Biotechnologies to Present 30-month Preclinical Safety and Expression Data for ADVM-022 ...

NEXT ARTICLE

More From BioPortfolio on "Adverum Biotechnologies to Present 30-month Preclinical Safety and Expression Data for ADVM-022 ..."

Quick Search